The heterogeneous expression levels of CREB3L1 in OC patients prompted us to examine both baseline expression and nuclear translocation of CREB3L1 in CD45-negative cancer cells after treatment with DOX, OVV, and a combination of OVV followed by DOX using clinical biopsies. This evidence concerns the gene PTPRC and cancer.